SOPHiA GENETICS continues to expand and opens new offices in Rolle (Switzerland) with the support of the State of Vaud

Rolle, September 1, 2021 – SOPHiA GENETICS, a world leader in data-driven medicine, today announced the opening of new offices in Rolle (VD). These new facilities will allow the growing company to expand its capacity to accommodate a new office space and a new R&D laboratory.

SOPHiA GENETICS, a flagship company in Lake Geneva’s Health Valley, was founded in 2011 at the EPFL Innovation Park in Lausanne, Switzerland. Throughout the company’s expansion, it opened its own offices in Saint-Sulpice (Switzerland) in 2014, as well as a laboratory on the Biotech Campus in Geneva. As the company continued to grow, it opened an R&D center in the French Basque Country and a U.S. headquarters in Boston. SOPHiA GENETICS now employs more than 450 people, including roughly 230 in Switzerland.

SOPHIA GENETICS will now take over new premises in Rolle, offering additional office space and a new R&D laboratory. The infrastructure of these new facilities is specially designed to accommodate various requirements from Experimental Quality Check to Supply Chain and more, offering a tailor-made environment to meet the company’s R&D activities.

Jurgi Camblong, CEO and Founder of SOPHiA GENETICS, is delighted with the opening of these new Swiss offices: “We have doubled our workforce in less than two years, so it was important for us to have infrastructures adapted to our needs. The collaboration with the State of Vaud throughout the process was very much appreciated; I would like to thank the canton for its support from the beginning. It has become a valuable partner in managing our growth.”

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.